1. Home
  2. ASTE vs GYRE Comparison

ASTE vs GYRE Comparison

Compare ASTE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASTE
  • GYRE
  • Stock Information
  • Founded
  • ASTE 1972
  • GYRE 2002
  • Country
  • ASTE United States
  • GYRE United States
  • Employees
  • ASTE N/A
  • GYRE N/A
  • Industry
  • ASTE Construction/Ag Equipment/Trucks
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASTE Industrials
  • GYRE Health Care
  • Exchange
  • ASTE Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • ASTE 1.1B
  • GYRE 897.1M
  • IPO Year
  • ASTE N/A
  • GYRE N/A
  • Fundamental
  • Price
  • ASTE $47.57
  • GYRE $7.28
  • Analyst Decision
  • ASTE Hold
  • GYRE Strong Buy
  • Analyst Count
  • ASTE 1
  • GYRE 1
  • Target Price
  • ASTE $41.00
  • GYRE $18.00
  • AVG Volume (30 Days)
  • ASTE 168.1K
  • GYRE 92.0K
  • Earning Date
  • ASTE 11-05-2025
  • GYRE 11-12-2025
  • Dividend Yield
  • ASTE 1.09%
  • GYRE N/A
  • EPS Growth
  • ASTE N/A
  • GYRE N/A
  • EPS
  • ASTE 2.01
  • GYRE 0.02
  • Revenue
  • ASTE $1,310,100,000.00
  • GYRE $102,189,000.00
  • Revenue This Year
  • ASTE $6.28
  • GYRE $16.80
  • Revenue Next Year
  • ASTE $7.50
  • GYRE $50.29
  • P/E Ratio
  • ASTE $23.72
  • GYRE $428.23
  • Revenue Growth
  • ASTE 1.17
  • GYRE N/A
  • 52 Week Low
  • ASTE $29.65
  • GYRE $6.11
  • 52 Week High
  • ASTE $50.83
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • ASTE 51.53
  • GYRE 44.66
  • Support Level
  • ASTE $47.38
  • GYRE $7.20
  • Resistance Level
  • ASTE $50.83
  • GYRE $7.72
  • Average True Range (ATR)
  • ASTE 1.27
  • GYRE 0.28
  • MACD
  • ASTE -0.11
  • GYRE -0.01
  • Stochastic Oscillator
  • ASTE 23.06
  • GYRE 28.58

About ASTE Astec Industries Inc.

Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: